Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C26H25F3N6O5 |
Molecular Weight | 558.5091 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CN(C[C@]1([H])[C@H]2NC(=O)[C@H](C)NC(=O)[C@H](C)N)C3=C(F)C=C4C(=O)C(=CN(C5=CC=C(F)C=C5F)C4=N3)C(O)=O
InChI
InChIKey=UUZPPAMZDFLUHD-VUJLHGSVSA-N
InChI=1S/C26H25F3N6O5/c1-10(30)24(37)31-11(2)25(38)32-20-14-7-34(8-15(14)20)23-18(29)6-13-21(36)16(26(39)40)9-35(22(13)33-23)19-4-3-12(27)5-17(19)28/h3-6,9-11,14-15,20H,7-8,30H2,1-2H3,(H,31,37)(H,32,38)(H,39,40)/t10-,11-,14-,15+,20+/m0/s1
Molecular Formula | C26H25F3N6O5 |
Molecular Weight | 558.5091 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.drugbank.ca/drugs/DB00685https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da9b26bb-d2d7-4113-a0f9-c6c2280f4875#Clinical_PharmacologyCurator's Comment: Description was created based on several sources, including
https://www.drugs.com/dosage/trovan.html
Sources: http://www.drugbank.ca/drugs/DB00685https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da9b26bb-d2d7-4113-a0f9-c6c2280f4875#Clinical_Pharmacology
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/dosage/trovan.html
Alatrofloxacin is a fluoroquinolone antibiotic developed as a mesylate salt and was sold under brand name Trovan, but was withdrawn from the U.S. market in 2001. Trovan was indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. After intravenous administration, alatrofloxacin is rapidly converted to trovafloxacin, which is responsible for therapeutic effect. Plasma concentrations of alatrofloxacin are below quantifiable levels within 5 to 10 minutes of completion of a 1 hour infusion.
CNS Activity
Originator
Sources: http://adisinsight.springer.com/drugs/800001875
Curator's Comment: # Pfizer
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL364 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12878530 |
|||
Target ID: CHEMBL347 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11892894 |
|||
Target ID: CHEMBL614429 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11892894 |
|||
Target ID: CHEMBL352 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20407243 |
|||
Target ID: CHEMBL354 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11418510 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | TROVAN PRESERVATIVE FREE Approved UseTrovan is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE: Trovan has not been studied in the treatment of osteomyelitis. Launch Date1997 |
|||
Sources: https://www.drugs.com/pro/trovan.html |
Curative | TROVAN Approved UseNosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated.
Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae.
Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species.
Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis.
Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. Launch Date1997 |
||
Curative | TROVAN Approved UseNosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated.
Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae.
Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species.
Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis.
Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. Launch Date1997 |
|||
Curative | TROVAN Approved UseNosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated.
Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae.
Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species.
Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis.
Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. Launch Date1997 |
|||
Curative | TROVAN PRESERVATIVE FREE Approved UseTrovan is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE: Trovan has not been studied in the treatment of osteomyelitis. Launch Date1997 |
|||
Curative | TROVAN PRESERVATIVE FREE Approved UseTrovan is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE: Trovan has not been studied in the treatment of osteomyelitis. Launch Date1997 |
|||
Curative | TROVAN PRESERVATIVE FREE Approved UseTrovan is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE: Trovan has not been studied in the treatment of osteomyelitis. Launch Date1997 |
|||
Curative | TROVAN PRESERVATIVE FREE Approved UseTrovan is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE: Trovan has not been studied in the treatment of osteomyelitis. Launch Date1997 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.1 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145 |
100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TROVAFLOXACIN serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
2.9 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
TROVAFLOXACIN serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
3.3 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145 |
300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TROVAFLOXACIN serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
TROVAFLOXACIN serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
2.9 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9935250 |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
TROVAFLOXACIN serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
11.8 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145 |
100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TROVAFLOXACIN serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
26.2 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
TROVAFLOXACIN serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
34.6 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145 |
300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TROVAFLOXACIN serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
9.4 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
TROVAFLOXACIN serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
32.2 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9935250 |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
TROVAFLOXACIN serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145 |
100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TROVAFLOXACIN serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
10.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
TROVAFLOXACIN serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
12.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145 |
300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TROVAFLOXACIN serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
9.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
TROVAFLOXACIN serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
13.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9935250 |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
TROVAFLOXACIN serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
22% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145 |
100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TROVAFLOXACIN serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
25.6% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
TROVAFLOXACIN serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
28.3% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145 |
300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TROVAFLOXACIN serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
20.3% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
TROVAFLOXACIN serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
1000 mg single, oral Highest studied dose |
healthy, 27 years n = 4 Health Status: healthy Age Group: 27 years Sex: M Population Size: 4 Sources: |
Other AEs: Nausea, Vomiting... Other AEs: Nausea (4 patients) Sources: Vomiting (1 patient) Lightheadedness (4 patients) |
200 mg 1 times / day steady, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: |
unhealthy, adult n = 881 Health Status: unhealthy Condition: chronic bronchitis or pneumonia Age Group: adult Sex: M+F Population Size: 881 Sources: |
Disc. AE: Gastrointestinal disorder NOS, CNS disorder (NOS)... AEs leading to discontinuation/dose reduction: Gastrointestinal disorder NOS (11 patient) Sources: CNS disorder (NOS) (4 patients) Dizziness (2 patients) Dermatitis (2 patients) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Vomiting | 1 patient | 1000 mg single, oral Highest studied dose |
healthy, 27 years n = 4 Health Status: healthy Age Group: 27 years Sex: M Population Size: 4 Sources: |
Lightheadedness | 4 patients | 1000 mg single, oral Highest studied dose |
healthy, 27 years n = 4 Health Status: healthy Age Group: 27 years Sex: M Population Size: 4 Sources: |
Nausea | 4 patients | 1000 mg single, oral Highest studied dose |
healthy, 27 years n = 4 Health Status: healthy Age Group: 27 years Sex: M Population Size: 4 Sources: |
Gastrointestinal disorder NOS | 11 patient Disc. AE |
200 mg 1 times / day steady, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: |
unhealthy, adult n = 881 Health Status: unhealthy Condition: chronic bronchitis or pneumonia Age Group: adult Sex: M+F Population Size: 881 Sources: |
Dermatitis | 2 patients Disc. AE |
200 mg 1 times / day steady, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: |
unhealthy, adult n = 881 Health Status: unhealthy Condition: chronic bronchitis or pneumonia Age Group: adult Sex: M+F Population Size: 881 Sources: |
Dizziness | 2 patients Disc. AE |
200 mg 1 times / day steady, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: |
unhealthy, adult n = 881 Health Status: unhealthy Condition: chronic bronchitis or pneumonia Age Group: adult Sex: M+F Population Size: 881 Sources: |
CNS disorder (NOS) | 4 patients Disc. AE |
200 mg 1 times / day steady, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: |
unhealthy, adult n = 881 Health Status: unhealthy Condition: chronic bronchitis or pneumonia Age Group: adult Sex: M+F Population Size: 881 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 4.0 |
yes | |||
Page: 4.0 |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Emergence of trimethoprim-resistant Escherichia coli in healthy persons in the absence of prophylactic or therapeutic antibiotics during travel to Guadalajara, Mexico. | 2001 |
|
In vitro susceptibility and eradication of Chlamydia pneumoniae cardiovascular strains from coronary artery endothelium and smooth muscle cells. | 2001 |
|
Latest industry information on the safety profile of levofloxacin in Japan. | 2001 |
|
Comparison of side effects of levofloxacin versus other fluoroquinolones. | 2001 |
|
History of quinolones and their side effects. | 2001 |
|
In vitro activity of fluoroquinolones (gatifloxacin, levofloxacin and trovafloxacin) and seven other antibiotics against Streptococcus pneumoniae. | 2001 Apr |
|
Comparative anti-staphylococcal effects of gemifloxacin and trovafloxacin in an in vitro dynamic model in terms of AUC/MIC and dose relationships. | 2001 Aug |
|
[In vitro activity of six fluoroquinolones and penicillin against 101 viridans group streptococci characterized by their susceptibility to erythromycin]. | 2001 Dec |
|
[Activity of new fluoroquinolones against clinical isolates of Acinetobacter baumannii]. | 2001 Dec |
|
Determining the frequency of resistance of Streptococcus pneumoniae to ciprofloxacin, levofloxacin, trovafloxacin, grepafloxacin, and gemifloxacin. | 2001 Dec |
|
Peripheral neuropathy associated with fluoroquinolones. | 2001 Dec |
|
Resistance to vancomycin, LY333328, ciprofloxacin and trovafloxacin of community-acquired and nosocomial strains of Enterococcus faecalis isolated in Badajoz (Spain) with and without high-level resistance to streptomycin and gentamicin. | 2001 Dec |
|
Differences between two new quinolones (gemifloxacin and trovafloxacin) and ciprofloxacin in their concentration-dependent killing of Streptococcus pneumoniae. | 2001 Dec |
|
Comparative activity of linezolid and other new agents against methicillin-resistant Staphylococcus aureus and teicoplanin-intermediate coagulase-negative staphylococci. | 2001 Dec |
|
pH-metric solubility. 3. Dissolution titration template method for solubility determination. | 2001 Dec |
|
Quinolones and false-positive urine screening for opiates by immunoassay technology. | 2001 Dec 26 |
|
Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin. | 2001 Jul |
|
Comparative in vitro bacteriostatic and bactericidal activity of trovafloxacin, levofloxacin and moxifloxacin against clinical and environmental isolates of Legionella spp. | 2001 Jul |
|
Use of broad spectrum antibiotics in six non-university Swiss hospitals. | 2001 Jul 28 |
|
Experimental intravitreal application of trovafloxacin in rabbits. | 2001 Jul-Aug |
|
[Are the antimicrobials used in community-acquired respiratory infection useful for preventing transmission of meningococcal disease? In vitro study]. | 2001 Jun |
|
A comparative study of the fluoroquinolone antibacterial agents on the action potential duration in guinea pig ventricular myocardia. | 2001 Nov |
|
Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin. | 2001 Nov |
|
Comparison of antimicrobial in vitro activities against Streptococcus pneumoniae independent of MIC susceptibility breakpoints using MIC frequency distribution curves, scattergrams and linear regression analyses. | 2001 Nov |
|
Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens. | 2001 Oct |
|
Seizures associated with fluoroquinolones. | 2001 Oct |
|
High rates of multiple antibiotic resistance in Streptococcus pneumoniae from healthy children living in isolated rural communities: association with cephalosporin use and intrafamilial transmission. | 2001 Oct |
|
Fluoroquinolone susceptibilities of efflux-mediated multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Burkholderia cepacia. | 2001 Oct |
|
Frequency of selection of fluoroquinolone-resistant mutants of Neisseria gonorrhoeae exposed to gemifloxacin and four other quinolones. | 2001 Oct |
|
Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers. | 2001 Sep |
|
Is more than one quinolone needed in clinical practice? | 2001 Sep |
|
Future of the quinolones. | 2001 Sep |
|
Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae. | 2001 Sep |
|
Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy. | 2001 Sep 15 |
|
Human research. Nigerian families sue Pfizer, testing the reach of U.S. law. | 2001 Sep 7 |
|
Drug company sued over research trial in Nigeria. | 2001 Sep 8 |
|
In vitro susceptibility of Stenotrophomonas maltophilia to various antimicrobial combinations. | 2001 Sep-Oct |
|
In vitro activity of novel fluoroquinolones against Streptococcus pneumoniae isolated from children with acute otitis media. | 2001 Sep-Oct |
|
Gatifloxacin: a review of its use in the management of bacterial infections. | 2002 |
|
A critical review of the fluoroquinolones: focus on respiratory infections. | 2002 |
|
Moxifloxacin sensitivity of respiratory pathogens in the United Kingdom. | 2002 Feb |
|
In vitro activity of clinafloxacin in comparison with other quinolones against Stenotrophomonas maltophilia clinical isolates in the presence and absence of reserpine. | 2002 Feb |
|
Antimicrobial resistance trends in community-acquired respiratory tract pathogens in the Western Pacific Region and South Africa: report from the SENTRY antimicrobial surveillance program, (1998-1999) including an in vitro evaluation of BMS284756. | 2002 Feb |
|
In vitro assessment of urinary isolates of ampicillin-resistant enterococci. | 2002 Feb |
|
Influence of CO(2) incubation on quinolone activity against Streptococcus pneumoniae and Haemophilus influenzae. | 2002 Jan |
|
Susceptibility of human isolates of Salmonella typhimurium DT 104 to antimicrobial agents used in human and veterinary medicine. | 2002 Jan |
|
Quinolone treatment for pediatric bacterial meningitis: a comparative study of trovafloxacin and ceftriaxone with or without vancomycin. | 2002 Jan |
|
Bactericidal mechanism of gatifloxacin compared with other quinolones. | 2002 Jan |
|
Antimicrobial susceptibilities among clinical isolates of extended-spectrum cephalosporin-resistant Gram-negative bacteria in a Taiwanese University Hospital. | 2002 Jan |
|
Activity of clinafloxacin, compared with six other quinolones, against Acinetobacter baumannii clinical isolates. | 2002 Mar |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/trovan.html
Nosocomial Pneumonia - 300 mg I.V. followed by 200 mg oral, 10–14 days
Community Acquired Pneumonia - 200 mg oral or 200 mg I.V. followed by 200 mg oral, 7–14 days
Gynecologic and Pelvic Infections - 300 mg I.V. followed by 200 mg oral, 7–14 days
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11418510
Trovafloxacin inhibited Escherichia coli growth with MIC50 = 0.125mg/L
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 16:19:44 GMT 2023
by
admin
on
Sat Dec 16 16:19:44 GMT 2023
|
Record UNII |
7QVV6I50DT
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C795
Created by
admin on Sat Dec 16 16:19:45 GMT 2023 , Edited by admin on Sat Dec 16 16:19:45 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C79898
Created by
admin on Sat Dec 16 16:19:45 GMT 2023 , Edited by admin on Sat Dec 16 16:19:45 GMT 2023
|
PRIMARY | |||
|
SUB05293MIG
Created by
admin on Sat Dec 16 16:19:45 GMT 2023 , Edited by admin on Sat Dec 16 16:19:45 GMT 2023
|
PRIMARY | |||
|
DTXSID4057893
Created by
admin on Sat Dec 16 16:19:45 GMT 2023 , Edited by admin on Sat Dec 16 16:19:45 GMT 2023
|
PRIMARY | |||
|
7QVV6I50DT
Created by
admin on Sat Dec 16 16:19:45 GMT 2023 , Edited by admin on Sat Dec 16 16:19:45 GMT 2023
|
PRIMARY | |||
|
7495
Created by
admin on Sat Dec 16 16:19:45 GMT 2023 , Edited by admin on Sat Dec 16 16:19:45 GMT 2023
|
PRIMARY | |||
|
Alatrofloxacin
Created by
admin on Sat Dec 16 16:19:45 GMT 2023 , Edited by admin on Sat Dec 16 16:19:45 GMT 2023
|
PRIMARY | |||
|
C106856
Created by
admin on Sat Dec 16 16:19:45 GMT 2023 , Edited by admin on Sat Dec 16 16:19:45 GMT 2023
|
PRIMARY | |||
|
146961-76-4
Created by
admin on Sat Dec 16 16:19:45 GMT 2023 , Edited by admin on Sat Dec 16 16:19:45 GMT 2023
|
PRIMARY | |||
|
DB09335
Created by
admin on Sat Dec 16 16:19:45 GMT 2023 , Edited by admin on Sat Dec 16 16:19:45 GMT 2023
|
PRIMARY | |||
|
141440
Created by
admin on Sat Dec 16 16:19:45 GMT 2023 , Edited by admin on Sat Dec 16 16:19:45 GMT 2023
|
PRIMARY | RxNorm | ||
|
Alatrofloxacin
Created by
admin on Sat Dec 16 16:19:45 GMT 2023 , Edited by admin on Sat Dec 16 16:19:45 GMT 2023
|
PRIMARY | |||
|
CHEMBL1201197
Created by
admin on Sat Dec 16 16:19:45 GMT 2023 , Edited by admin on Sat Dec 16 16:19:45 GMT 2023
|
PRIMARY | |||
|
102
Created by
admin on Sat Dec 16 16:19:45 GMT 2023 , Edited by admin on Sat Dec 16 16:19:45 GMT 2023
|
PRIMARY | |||
|
100000085239
Created by
admin on Sat Dec 16 16:19:45 GMT 2023 , Edited by admin on Sat Dec 16 16:19:45 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PRODRUG |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|